Published in Diabetes Week, September 21st, 2009
The protein encoded by the gene known as I'B kinase e (IKKe) belongs to a class of enzymes, the kinases, which typically make for good drug targets because they are relatively easy to block, according to the researchers. Even better in terms of its therapeutic promise, IKKe loss seems to have many beneficial effects. Mice without the gene are protected against weight gain, chronic inflammation, fatty liver and...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Diabetes Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.